| Drug General Information |
| Drug ID |
D0C8UE
|
| Former ID |
DCL000077
|
| Drug Name |
Capridine-beta
|
| Synonyms |
Apremilast; CC 10004; Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Psoriasis [ICD9: 696; ICD10:L40]
|
Discontinued in Phase 4 |
[1]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Company |
Gardant Pharma; Celgene
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H25NO7S
|
| Canonical SMILES |
CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C<br />3)CC(=O)C)OC
|
| InChI |
1S/C23H25NO7S/c1-5-31-20-12-15(9-10-19(20)30-3)18(13-32(4,28)29)24-22(26)17-8-6-7-16(11-14(2)25)21(17)23(24)27/h6-10,12,18H,5,11,13H2,1-4H3/t18-/m1/s1
|
| InChIKey |
MUKPBEDSDFRMNQ-GOSISDBHSA-N
|
| CAS Number |
CAS 608141-41-9
|
| PubChem Compound ID |
|
| SuperDrug ATC ID |
L04AA32
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 2 |
Target Info |
Inhibitor |
[2]
|
|---|
| Cell division protein kinase 6 |
Target Info |
Inhibitor |
[2]
|
| Cell division protein kinase 4 |
Target Info |
Inhibitor |
[2]
|
| PDE4 |
Target Info |
Inhibitor |
[3],
[4]
|
|
KEGG Pathway
|
FoxO signaling pathway
|
|
Cell cycle
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Prostate cancer
|
|
Small cell lung cancerhsa04110:Cell cycle
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Glioma
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancerhsa04110:Cell cycle
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
HTLV-I infection
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
p53 pathway
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by PRL
|
|
p73 transcription factor network
|
|
E2F transcription factor network
|
|
ATR signaling pathway
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
FoxO family signaling
|
|
FOXM1 transcription factor network
|
|
BARD1 signaling events
|
|
p53 pathway
|
|
Regulation of retinoblastoma proteinp73pathway:p73 transcription factor network
|
|
Coregulation of Androgen receptor activity
|
|
C-MYB transcription factor network
|
|
IL2 signaling events mediated by STAT5
|
|
Regulation of retinoblastoma proteinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATF-2 transcription factor network
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
G0 and Early G1
|
|
Activation of ATR in response to replication stress
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
SCF(Skp2)-mediated degradation of p27/p21
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
DNA Damage/Telomere Stress Induced Senescence
|
|
Processing of DNA double-strand break ends
|
|
G2 Phase
|
|
Orc1 removal from chromatin
|
|
Cyclin E associated events during G1/S transition
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
p53-Dependent G1 DNA Damage Response
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
Meiotic recombination
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-2559580:Oxidative Stress Induced Senescence
|
|
Oncogene Induced Senescence
|
|
Cyclin D associated events in G1R-HSA-2559580:Oxidative Stress Induced Senescence
|
|
RMTs methylate histone arginines
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Ubiquitin-dependent degradation of Cyclin D1
|
|
Cyclin D associated events in G1
|
|
WikiPathways
|
DNA Damage Response
|
|
ID signaling pathway
|
|
DNA Replication
|
|
G1 to S cell cycle control
|
|
M/G1 Transition
|
|
S Phase
|
|
Meiotic Recombination
|
|
Aryl Hydrocarbon Receptor
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Synthesis of DNA
|
|
Regulation of DNA replication
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Cell Cycle
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
|
Wnt Signaling Pathway Netpath
|
|
Metastatic brain tumor
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
miRNAs involved in DNA damage response
|
|
Ovarian Infertility Genes
|
|
PPAR Alpha Pathway
|
|
Bladder Cancer
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. |
|---|
| REF 2 | Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. |
|---|
| REF 3 | CC-10004 . Curr Opin Investig Drugs. 2005 May;6(5):518-25. |
|---|
| REF 4 | Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. |
|---|
